Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update
International Journal of Andrology, 08/15/2011
Koychev D et al. – Prognosis in multiply relapsed and primary cisplatin–refractory patients is generally poor. A number of mechanisms of cisplatin resistance and potential drug targets like global methylation and BRAF mutation status are under investigation in refractory germ cell tumours (GCT).






